Susan Galbraith (AstraZeneca)
June 28, 2021 09:43 AM EDT
People

As­traZeneca CEO Pas­cal So­ri­ot taps vet­er­an can­cer re­searcher Su­san Gal­braith for top on­col­o­gy post

John Carroll

Editor & Founder

When Su­san Gal­braith joined the can­cer R&D team at As­traZeneca in 2010, the phar­ma gi­ant was un­der­go­ing a bru­tal take­down at the hands of an­a­lysts …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

A service from the Financial Times